PE20130659A1 - Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos - Google Patents

Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos

Info

Publication number
PE20130659A1
PE20130659A1 PE2012002489A PE2012002489A PE20130659A1 PE 20130659 A1 PE20130659 A1 PE 20130659A1 PE 2012002489 A PE2012002489 A PE 2012002489A PE 2012002489 A PE2012002489 A PE 2012002489A PE 20130659 A1 PE20130659 A1 PE 20130659A1
Authority
PE
Peru
Prior art keywords
weight
prepare
methods
devices including
matrix
Prior art date
Application number
PE2012002489A
Other languages
English (en)
Inventor
Anu Mahashabde
Jiaxiang Tsao
Original Assignee
Teva Womens Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Womens Health Inc filed Critical Teva Womens Health Inc
Publication of PE20130659A1 publication Critical patent/PE20130659A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/48—Devices for preventing wetting or pollution of the bed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nursing (AREA)
  • Medicinal Preparation (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN DISPOSITIVO INTRAVAGINAL QUE COMPRENDE: A) UNA PRIMERA MATRIZ ANULAR QUE REPRESENTA DE 80% A 95% EN PESO DEL DISPOSITIVO, FORMADA POR UN POLIMERO DE POLISILOXANO HALOGENADO TAL COMO 3,3,3-TRIFLUOROPROPILMETILDIMETILPOLISILOXANO, Y QUE COMPRENDE i) UNA CAVIDAD QUE SE EXTIENDE DE 10° A 180° ALREDEDOR DEL PERIMETRO DE LA PRIMERA MATRIZ, Y ii) UNA PARED DE CAVIDAD QUE TIENE UN ESPESOR UNIFORME DE 1mm A 4mm Y QUE CONTIENE A LA CAVIDAD; B) UNA SEGUNDA MATRIZ QUE REPRESENTA DE 5% A 50% EN PESO DEL DISPOSITIVO, FORMADA POR UN POLIMERO DE POLISILOXANO, Y QUE COMPRENDE UN AGENTE ANTICOLINERGICO TAL COMO OXIBUTININA EN UNA CANTIDAD DE 20% A 70% EN PESO DE LA SEGUNDA MATRIZ QUE SE DISPERSA DE FORMA HOMOGENEA EN LA MISMA. TAMBIEN SE REFIERE A UN PROCESO DE PRODUCCION DEL DISPOSITIVO INTRAVAGINAL. DICHO DISPOSITIVO PROPORCIONA UNA FORMA DE ADMINISTRACION DE OXIBUTININA QUE REDUCE SUS EFECTOS SECUNDARIOS ANTICOLINERGICOS
PE2012002489A 2010-06-22 2011-06-22 Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos PE20130659A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35732510P 2010-06-22 2010-06-22

Publications (1)

Publication Number Publication Date
PE20130659A1 true PE20130659A1 (es) 2013-06-15

Family

ID=45372076

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002489A PE20130659A1 (es) 2010-06-22 2011-06-22 Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos

Country Status (15)

Country Link
US (1) US20120053534A1 (es)
EP (1) EP2585011A4 (es)
JP (1) JP2013535992A (es)
KR (1) KR20130045332A (es)
CN (1) CN103179926A (es)
AR (1) AR088410A1 (es)
AU (1) AU2011270997A1 (es)
BR (1) BR112012032951A2 (es)
CA (1) CA2803874A1 (es)
EA (1) EA201291298A1 (es)
MX (1) MX2013000003A (es)
PE (1) PE20130659A1 (es)
SG (2) SG186814A1 (es)
TW (1) TW201212939A (es)
WO (1) WO2011163358A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11717477B2 (en) 2018-04-10 2023-08-08 Ligalli B.V. Vaginal systemic drug delivery
CN112689471A (zh) * 2018-07-12 2021-04-20 普瑞玛太普公司 阴道温度传感设备和方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US5034189A (en) * 1985-08-27 1991-07-23 The Regents Of The University Of California Fluorescent probe for rapid measurement of analyte concentration
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2255266T3 (es) * 1998-05-01 2006-06-16 Duramed Pharmaceuticals, Inc. Procedimiento de fabricacion por moldeo po inyeccion para dispositivos de liberacion controlada y dispositivo asi producido.
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
AU2001258442A1 (en) * 2000-05-10 2001-11-20 Leiras Oy Drug delivery device, especially for the delivery of levonorgestrel
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US20070043332A1 (en) * 2003-07-10 2007-02-22 Galen (Chemiclas) Liimited Intravaginal drug delivery devices
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006084083A2 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Devices for delivering agents to a vaginal tract
CA2618349C (en) * 2005-08-11 2016-05-31 Massachusetts Institute Of Technology Intravesical drug delivery device and method
EP1933833B8 (en) * 2005-09-02 2011-09-14 Theravida, Inc. Therapy for the treatment of overactive bladder
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
DK2359807T3 (en) * 2008-02-04 2017-10-16 Ferring Bv Monolithic vaginal rings comprising progesterone and methods of preparation and use thereof
EP2106792A1 (en) * 2008-04-02 2009-10-07 Pelvipharm Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
US20100040671A1 (en) * 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof

Also Published As

Publication number Publication date
EA201291298A1 (ru) 2013-09-30
BR112012032951A2 (pt) 2018-02-27
TW201212939A (en) 2012-04-01
MX2013000003A (es) 2013-04-29
SG186814A1 (en) 2013-02-28
WO2011163358A2 (en) 2011-12-29
AR088410A1 (es) 2014-06-11
CN103179926A (zh) 2013-06-26
EP2585011A2 (en) 2013-05-01
SG10201504864UA (en) 2015-07-30
WO2011163358A3 (en) 2012-03-01
JP2013535992A (ja) 2013-09-19
EP2585011A4 (en) 2014-10-15
KR20130045332A (ko) 2013-05-03
AU2011270997A1 (en) 2013-01-10
CA2803874A1 (en) 2011-12-29
US20120053534A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
CL2015002145A1 (es) Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014)
NI201600138A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y metodos para su elaboración y uso
SG10201808743VA (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
EA201691193A1 (ru) Система доставки лекарственных средств
MX2012015187A (es) Metodo para suministrar un agente activo.
DOP2012000170A (es) Proceso para la fabricacion de un agente farmaceuticamante activo
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
AR093151A1 (es) Material polimerico para aislacion de recipientes
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
MY191875A (en) Solid dosage form
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
PH12014502834A1 (en) Pharmaceutical form for extended release of active substances
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
PE20130659A1 (es) Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
NZ710949A (en) Modified glycolipids and methods of making and using the same
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
CA3081484A1 (en) Finished fibrous structures and methods of their use and preparation
CL2013003488A1 (es) Dispositivo intravaginal que comprende un bolsillo que contiene una matriz con un agente anticolinérgico, donde la pared del bolsillo tiene un espesor uniforme; método para la fabricación de un dispositivo intravaginal (divisional de solicitud n°3658-12)”.

Legal Events

Date Code Title Description
FD Application declared void or lapsed